Concepedia

Author

Kirsten Nagashima

Progenics Pharmaceuticals (United States)

Also Known As

K A Nagashima, K NAGASHIMA, K Nagashima, K. Nagashima, Kiichi Nagashima, Kirsten A. Nagashima, Kirsten Nagashima, Kirsten A. Nagashima

59

Publications

5.7K

Citations

15

H-Index

42

Concepts

All Affiliations

Progenics Pharmaceuticals (United States)Aaron Diamond AIDS Research CenterRockefeller UniversityRegeneron (United States)Cornell University
KN

About

Kirsten Nagashima is an author at Progenics Pharmaceuticals (United States) specializing in medicine, immunology, and hiv.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

4.3K

2

Cell Biology

3

3

3.3K

3

Health Sciences

1

1

82

4

Natural Sciences

1

1

759

5

Social Sciences

1

1

17

Kirsten Nagashima

×

15

Publications

5.6K

Citations

15

H-Index

YearCitations

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

Tatjana Dragic, Virginia Litwin, Graham P. Allaway,

Nature

1996

3.2K

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor

G A Donzella, Dominique Schols, Steven Lin,

Nature Medicine

1998

759

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

Audrey Le Floc’h, Jeanne Allinne, Kirsten Nagashima,

Allergy

2019

448

Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5

William C. Olson, Gwénaël Rabut, Kirsten Nagashima,

Journal of Virology

1999

226

Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140

Alexandra Trkola, Thomas J. Ketas, Kirsten Nagashima,

Journal of Virology

2001

225

Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry

Tatjana Dragic, Alexandra Trkola, Steven Lin,

Journal of Virology

1998

216

Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542

Jeffrey M. Jacobson, Robert J. Israel, Israel Lowy,

Antimicrobial Agents and Chemotherapy

2004

123

Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 and T‐20 Are Potently Synergistic in Blocking Virus‐Cell and Cell‐Cell Fusion

Kirsten Nagashima, Daniah A. D. Thompson, Soraya I. Rosenfield,

The Journal of Infectious Diseases

2001

105

Protection Against Clostridium difficile Infection With Broadly Neutralizing Antitoxin Monoclonal Antibodies

Andre J. Marozsan, Dangshe Ma, Kirsten Nagashima,

The Journal of Infectious Diseases

2012

82

IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline

George Scott, Seblewongel Asrat, Jeanne Allinne,

Cytokine

2022

79

Page 1